Mono Pharmacre Ltd Stock Price Today (NSE: MONOPHARMA)
Fundamental Score
Mono Pharmacre Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Mono Pharmacre Ltd share price today is ₹12.60, up +0.00% on NSE/BSE as of 20 February 2026. Mono Pharmacre Ltd (MONOPHARMA) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹37.02 (Cr). The 52-week high for MONOPHARMA share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 44.60x, MONOPHARMA is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 10.42% and a debt-to-equity ratio of 1.76.
Mono Pharmacre Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Mono Pharmacre Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Financial Analysis of Mono Pharmacre Share Price: A Risk Manager's Perspective
The pharmaceutical sector is currently navigating a landscape defined by increasing R&D costs coupled with intense generic competition. This analysis examines the financial stability of Mono Pharmacre Ltd, focusing specifically on factors influencing the Mono Pharmacre share price. The current price stands at ₹10.85. A key metric to assess is the Price-to-Earnings (PE) ratio, which currently sits at 44.6. This indicates that investors are paying ₹44.6 for every ₹1 of Mono Pharmacre's earnings. This is important to consider when evaluating the stock's valuation relative to its potential.
A crucial aspect of financial stability is profitability. Mono Pharmacre's Return on Capital Employed (ROCE) is currently 11.0%. ROCE reflects how efficiently a company is using its capital to generate profits. An ROCE of 11.0% suggests reasonable efficiency, but further investigation is needed to determine if this is sustainable and competitive within the pharmaceutical industry. A consistently high ROCE can contribute to a wider economic moat, as it signals an ability to generate above-average returns compared to competitors. This, however, requires consistent operational excellence over time.
Comparing Mono Pharmacre to its peers is insightful. For instance, while not commenting on their investment merits, we can observe differences in management quality compared to a company like
Mankind Pharma Ltd. Strong management teams can effectively navigate regulatory hurdles, optimize operational efficiency, and drive innovation. This is important to keep in mind. While specific data isn't readily available in this overview, deeper investigation of management track records and strategies of both companies would be required to make a more informed assessment.This financial analysis forms part of a larger, 80-parameter fundamental audit of Mono Pharmacre Ltd, verified by Sweta Mishra. This comprehensive audit delves into aspects beyond share price and PE ratio, like debt levels, cash flow generation, and future growth prospects. This assessment is observational and does not provide any investment recommendations. The intent is to analyze the factors influencing Mono Pharmacre's share price and financial standing within the competitive pharmaceutical sector.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Mono Pharmacre Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of MONOPHARMA across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Balanced Promoter Holding (56.72%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Premium Valuation Risk (P/E: 44.60x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-99.13%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-23.94%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Elevated Debt Levels (D/E: 1.76)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Weak Interest Coverage (1.35x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Mono Pharmacre Ltd Financial Statements
Comprehensive financial data for Mono Pharmacre Ltd including income statement, balance sheet and cash flow
About MONOPHARMA (Mono Pharmacre Ltd)
Mono Pharmacre Ltd (MONOPHARMA) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹37.02 (Cr). Mono Pharmacre Ltd has delivered a Return on Equity (ROE) of 10.42% and a ROCE of 11.00%. The debt-to-equity ratio stands at 1.76, reflecting the company's capital structure. Investors tracking MONOPHARMA share price can monitor key metrics including P/E ratio, promoter holding of 56.72%, and quarterly earnings growth.
Company Details
MONOPHARMA Share Price: Frequently Asked Questions
What is the current share price of Mono Pharmacre Ltd (MONOPHARMA)?
As of 20 Feb 2026, 06:17 am IST, Mono Pharmacre Ltd share price is ₹12.60. The MONOPHARMA stock has a market capitalisation of ₹37.02 (Cr) on NSE/BSE.
Is MONOPHARMA share price Overvalued or Undervalued?
MONOPHARMA share price is currently trading at a P/E ratio of 44.60x, compared to the industry average of 31.77x. Based on this relative valuation, the Mono Pharmacre Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of MONOPHARMA share price?
The 52-week high of MONOPHARMA share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Mono Pharmacre Ltd share price?
Key factors influencing MONOPHARMA share price include quarterly earnings growth (Sales Growth: -23.94%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Mono Pharmacre Ltd a good stock for long-term investment?
Mono Pharmacre Ltd shows a 5-year Profit Growth of N/A% and an ROE of 10.42%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 1.76 before investing in MONOPHARMA shares.
How does Mono Pharmacre Ltd compare with its industry peers?
Mono Pharmacre Ltd competes with major peers in the Pharmaceuticals. Investors should compare MONOPHARMA share price P/E of 44.60x and ROE of 10.42% against the industry averages to determine competitive standing.
What is the P/E ratio of MONOPHARMA and what does it mean?
MONOPHARMA share price has a P/E ratio of 44.60x compared to the industry average of 31.77x. Investors pay ₹45 for every ₹1 of annual earnings.
How is MONOPHARMA performing according to Bull Run's analysis?
MONOPHARMA has a Bull Run fundamental score of 11.8/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does MONOPHARMA belong to?
MONOPHARMA operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Mono Pharmacre Ltd share price.
What is Return on Equity (ROE) and why is it important for MONOPHARMA?
MONOPHARMA has an ROE of 10.42%, which shows decent profitability but room for improvement. ROE measures how efficiently Mono Pharmacre Ltd generates profits from shareholders capital.
How is MONOPHARMA debt-to-equity ratio and what does it indicate?
MONOPHARMA has a debt-to-equity ratio of 1.76, which indicates high leverage that increases financial risk.
What is MONOPHARMA dividend yield and is it a good dividend stock?
MONOPHARMA offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Mono Pharmacre Ltd shares.
How has MONOPHARMA share price grown over the past 5 years?
MONOPHARMA has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in MONOPHARMA and why does it matter?
Promoters hold 56.72% of MONOPHARMA shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Mono Pharmacre Ltd.
What is MONOPHARMA market capitalisation category?
MONOPHARMA has a market capitalisation of ₹37 crores, placing it in the Small-cap category.
How volatile is MONOPHARMA stock?
MONOPHARMA has a beta of N/A. A beta > 1 suggests the Mono Pharmacre Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is MONOPHARMA operating profit margin trend?
MONOPHARMA has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is MONOPHARMA quarterly performance?
Recent quarterly performance shows Mono Pharmacre Ltd YoY Sales Growth of -23.94% and YoY Profit Growth of -99.13%.
What is the institutional holding pattern in MONOPHARMA?
MONOPHARMA has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Mono Pharmacre Ltd stock.